

# Neurology®

## Table of Contents

Volume 89, Number 11, September 12, 2017  
Neurology.org

THE MOST WIDELY READ AND HIGHLY CITED PEER-REVIEWED  
NEUROLOGY JOURNAL



### IN FOCUS

- 1097 Spotlight on the September 12 issue
- 1161 This Week's Neurology® Podcast

### EDITORIALS

- 1098 Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?  
*H. Wiendl, D. Bourdette, and O. Ciccarelli*
- 1101 Immune checkpoint inhibitor therapy: A double-edged sword?  
*H.J. Kim and A. Evoli*
- 1103 The virtual house call: A 21st-century innovation in the care of patients with Parkinson disease  
*D.R. Shprecher and J.J. Majersik*
- 1105 As the world turns, why do some people adapt to vestibular failure and others do not?  
*S.L. Galetta*

### ARTICLES

- 1107 Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy  
*E. Havrdova, D.L. Arnold, J.A. Cohen, H.-P. Hartung, E.J. Fox, G. Giovannoni, S. Schippling, K.W. Selmaj, A. Traboulsee, D.A.S. Compston, D.H. Margolin, K. Thangavelu, C.E. Rodriguez, D. Jody, R.J. Hogan, P. Xenopoulos, M.A. Panzara, and A.J. Coles, on behalf of CARE-MS I and CAMMS03409 Investigators*  
**OPEN** ▲ Editorial, p. 1098; see also p. 1117
- 1117 Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings  
*A.J. Coles, J.A. Cohen, E.J. Fox, G. Giovannoni, H.-P. Hartung, E. Havrdova, S. Schippling, K.W. Selmaj, A. Traboulsee, D.A.S. Compston, D.H. Margolin, K. Thangavelu, M.C. Chiriac, D. Jody, P. Xenopoulos, R.J. Hogan, M.A. Panzara, and D.L. Arnold, on behalf of CARE-MS II and CAMMS03409 Investigators*  
**OPEN** ▲ Editorial, p. 1098; see also p. 1107
- 1127 Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan  
*S. Suzuki, N. Ishikawa, F. Konoeda, N. Seki, S. Fukushima, K. Takahashi, H. Uhara, Y. Hasegawa, S. Inomata, Y. Otani, K. Yokota, T. Hirose, R. Tanaka, N. Suzuki, and M. Matsui*  
Editorial, p. 1101

- 1135 Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial  
*G. Beecher, D. Anderson, and Z.A. Siddiqi*  
▲
- 1142 Direct oral anticoagulant- vs vitamin K antagonist-related nontraumatic intracerebral hemorrhage  
*G. Tsivgoulis, V.-A. Lioutas, P. Varelas, A.H. Katsanos, N. Goyal, R. Mikulik, K. Barlinn, C. Krogias, V.K. Sharma, K. Vadikolias, E. Dardiotis, T. Karapanayiotides, A. Pappa, C. Zompola, S. Triantafyllou, O. Kargiotis, M. Ioakeimidis, S. Giannopoulos, A. Kerro, A. Tsantes, C. Mehta, M. Jones, C. Schroeder, C. Norton, A. Bonakis, J. Chang, A.W. Alexandrov, P. Mitsias, and A.V. Alexandrov*  
📖
- 1152 National randomized controlled trial of virtual house calls for Parkinson disease  
*C.A. Beck, D.B. Beran, K.M. Biglan, C.M. Boyd, E.R. Dorsey, P.N. Schmidt, R. Simone, A.W. Willis, N.B. Galifianakis, M. Katz, C.M. Tanner, K. Dodenhoff, J. Aldred, J. Carter, A. Fraser, J. Jimenez-Shahed, C. Hunter, M. Spindler, S. Reichwein, Z. Mari, B. Dunlop, J.C. Morgan, D. McLane, P. Hickey, L. Gauger, I.H. Richard, N.I. Mejia, G. Bwala, M. Nance, L.C. Shih, C. Singer, S. Vargas-Parra, C. Zadikoff, N. Okon, A. Feigin, J. Ayan, C. Vaughan, R. Pahwa, R. Dhall, A. Hassan, S. DeMello, S.S. Riggare, P. Wicks, M.A. Achey, M.J. Elson, S. Goldenthal, H.T. Keenan, R. Korn, H. Schwarz, S. Sharma, E.A. Stevenson, and W. Zhu, on behalf of the Connect. Parkinson Investigators*  
📖 ▲ Editorial, p. 1103
- 1162 Utilization of rehabilitation therapy services in Parkinson disease in the United States  
*M.E. Fullard, D.P. Thibault, A. Hill, J. Fox, D.E. Bhatti, M.A. Burack, N. Dahodwala, E. Haberfeld, D.S. Kern, O.S. Klepitskava, E. Urrea-Mendoza, P. Myers, J. Nutt, M.R. Rafferty, J.M. Schwalb, L.M. Shulman, and A.W. Willis, on behalf of the Parkinson Study Group Healthcare Outcomes and Disparities Working Group*
- 1170 <sup>18</sup>F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome  
*H. Cho, M.S. Baek, J.Y. Choi, S.H. Lee, J.S. Kim, Y.H. Ryu, M.S. Lee, and C.H. Lyoo*

CONTINUED

# Neurology®

## Table of Contents

continued



- 1179 Downregulation of early visual cortex excitability mediates oscillopsia suppression  
*H. Ahmad, R.E. Roberts, M. Patel, R. Lobo, B. Seemungal, Q. Arshad, and A. Bronstein*  
**OPEN** Editorial, p. 1105

- 1186 Staying in service with posttraumatic headache: A retrospective cohort study of patient outcome  
*A.G. Finkel, J.S. Klaric, J.A. Yerry, and Y.S. Choi*

### CLINICAL/SCIENTIFIC NOTES

- 1195 Rare case of ribose 5 phosphate isomerase deficiency with slowly progressive leukoencephalopathy  
*N. Naik, A. Shah, M.M.C. Wamelink, M.S. van der Knaap, and D. Hingwala*

### REFLECTIONS: NEUROLOGY AND THE HUMANITIES

- 1197 Ancillary staff: A difficult kind of listening  
*D. Krieger*

### VIDEO NEUROIMAGES

- 1198 Proptosis: A forgotten observation by Miller Fisher on his syndrome  
*S.A. Braksick, A.A. Rabinstein, and E.F.M. Wijdsicks*

### RESIDENT & FELLOW SECTION

- e129 Emerging Subspecialties in Neurology: Autoimmune neurology  
*A.S. López-Chiriboga and S.L. Clardy*

- e134 Teaching *NeuroImages*: Early-onset dementia and demyelinating neuropathy disclosing cerebrotendinous xanthomatosis  
*P.V.S. Souza, T. Bortholin, F.G.M. Naylor, W.B.V.R. Pinto, and A.S.B. Oliveira*

### WRITECLICK® EDITOR'S CHOICE

- 1199 Editors' Note  
*C. Karam and R.C. Griggs*
- 1199 Letter re: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis  
*F.A. Davis*
- 1200 Author response: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis  
*L. Filli, B. Zörner, T. Killeen, and M. Linnebank*
- 1200 Letter re: A model for predicting the growth of unruptured intracranial aneurysms: Beyond fortune telling  
*S. Munakomi*
- 1200 Editorialist response: A model for predicting the growth of unruptured intracranial aneurysms: Beyond fortune telling  
*D. Ding*

### CORRECTION

- 1200 Motor neuron disease in patients with HIV infection

### DEPARTMENT

In the Next Issue of *Neurology*®

Podcast at [Neurology.org](http://Neurology.org) CME Video Patient Page LOE classification LOE recommendation

Facebook [tinyurl.com/neurologyfan](https://www.facebook.com/Neurologyfan) Twitter [twitter.com/GreenJournal](https://twitter.com/GreenJournal)



**Cover image:** Depiction of the experimental protocol implemented to probe how visual motion adaptation mediates oscillopsia suppression. See page 1179.

Look for Publish Ahead of Print articles and editorials under the Ahead of Print tab at [Neurology.org](http://Neurology.org)